Cefotaxime pharmacokinetics after oral application in the form of 3α,7α-dihydroxy-12-keto-5β-cholanate microvesicles in rat

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 34, Issue 1, 2009, Pages 31-36

  Golocorbin Kon, Svetlana ^a   Mikov, Momir ^a   Arafat, Mousab ^b   Lepojevic, Zika ^c   Mikov, Ivan ^a   Sahman Zaimovic, Majda ^a   Tomic, Zdenko ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

3 ; 7 dihydroxy 12 keto 5 cholanate; Bile acid; Cefotaxime; Microvesicles; Pharmacokinetics; Rat

Indexed keywords

3ALPHA,7ALPHA DIHYDROXY 12 KETO 5BETA CHOLANATE; BILE SALT; CEFOTAXIME; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MICROENCAPSULATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; WISTAR RAT;

EID: 65649130489     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191381     Document Type: Article

References (40)

1. Rosseel M.T., Vandewoude K.H., (2004): Liquid chromatographic determination of the plasma concentrations of cefotaxime and desacetylcefotaxime in plasma of critically ill patients. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 811, 159-163.
2. USP NF - United States Pharmacopeia and National Formulary, United States Pharmacopeial Convention Inc., Rockville, MD, USA, 26th Edition, 2003
3. Sharma P., Varma M.V., Chawla H.P., Panchagnula R. (2005): Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers. Farmaco, 6, 884-893.
4. Berge S.M., Henderson N.L., Frank M.J. (1983): Kinetics and mechanism of degradation of cefotaxime sodium in aqueous solution. J. Pharm. Sci., 72, 59-63.
5. Das Gupta V. (1984): Stability of cefotaxime sodium as determined by high-performance liquid chromatography. J. Pharm. Sci., 73, 565-567.
6. Fabre H., Eddine N.H., Berge G. (1984): Degradation kinetics in aqueous solution of cefotaxime sodium, a third-generation cephalosporin. J. Pharm. Sci., 73, 611-618.
7. Esmieu F., Guibert J., Rosenkilde H.C., Ho I., Le Go A. (1980): Pharmacokinetics of cefotaxime in normal human volunteers. J. Antimicrob. Chemother., 6 Suppl A, 83-92.
8. Wise R., Wright N., et al. (1981): Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease. Antimicrob. Agents Chemother., 19, 526-531.
9. Mesiha M.S., Ponnapula P., Plakogiannis F. (2002): Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and alpha tocoferol dispersions. Int. J. Pharm., 249, 1-5.
10. Michael S., Thole M., Dillman R., Fahr A., Drewe J., Fricker F. (2000): Improvement of intestinal absorption by synthetic bile acid derivative, cholylsarcosine. Eur. J. Pharm. Sci,, 10, 133-140.
11. Mikov M., Al-Salami H., Golocorbin-Kon S., Skrbic R., Raskovic A., Fawcett J.P. (2008): The influence of 3α,7α-dihydroxy-12-oxo-5β-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur. J. Drug Metabol. Pharmacokinet, 33, 137-142.
12. Mrestani Y., Bretschneider B., Hartl A., Neubert R.H.H. (2003): In vitro and in vivo studies of cefiprom using bile salts as absorption enhancers. J. Pharm. Pharmacol., 55, 1601-1606.
13. Mikov M., Raskovic A., Jakovljevic E., Dudvarski D., Fawcett J.P. (2005): Influence of the bile salt sodium 3α,7α-dihydroxy-12-oxo-5β-cholanate on ampicillin pharmacokinetics in rats. Asian J. Drug Metabol. Pharmacokinet., 5, 197-200.
14. Mikov M., Kevresan S., Kuhajda K., Jakovljevic V., Vasovic V. (2004): 3α,7α-dihydroxy-12-oxo-5β-cholanate as blood-brain barrier permeator. Pol. J. Pharmacol., 56, 367-371.
15. Sharma P., Chawla H.P., Panchagnula R. (2002): LC determination of cephalosporins in in vitro rat intestinal sac absorption model. J. Pharm. Biomed. Anal., 27, 39-50.
16. Ling S.S.N., Magrosso E., Khan N.A. K., Yen K.H. (2006): Enhanced oral bioavailability and intestinal lymphatic transport of hydrophilic drug using liposomes. Drug Dev. Ind. Pharm., 32, 335-345.
17. Miljkovic D., Kuhajda K., Hranisavljevic J. (1996): Selective C-12 oxidation of cholic acid. J. Chem. Res.; Suppl, 106-107.
18. Russell D.G., Alexander J. (1988): Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J. Immunol., 140, 1274-1279.
19. Ling S.S.N., Yuen K.H., Barker S.A. (2002): Simple Liquid chromatographic method for determination of cefotaxime in human and rat plasma. J.. Chrom.. B, 783, 297-301.
20. Hsieh D. (ed). Drug Permeation Enhancement Theory and Applications. Marcel Dekker Inc, New York, 1994
21. Mikov M., Fawcett J.P. (editors). In: (Mikov M., Fawcett J.P., Kuhajda K., Kevresan S., Kandrac J., eds) Bile acids: Chemistry, biosynthesis, analysis, chemical and metabolic transformations. Mediset Publisher, Geneva, 2007.
22. Alberts B., Bary D., Lewis J., Raff M., Roberts K., Watson J. (eds): Molecular Biology of the Cell. Garland, New York, 1983
23. Bretschneider B., Brandsch M., Neubert R. (1999): Intestinal transport of beta-lactam antibiotics: Analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm. Res., 16, 55-61.
24. Van Bambeke F., Michot J-M., Tulkens P.M. (2003): Antibiotic efflux pumps in eucariotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodimamics. J. Antimicrob. Chemother., 51, 1067-1077.
25. Maincent P., Le Verge R., Sado P., Couvreur P., Devissaquet J.P. (1986): Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles. J. Pharm. Sci,, 75, 955-958.
26. Iwanaga K., Ono S., Narioka K., Kakemi M., Morimoto K., Yamashita S., Namba Y., Oku N., (1999): Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J. Pharm. Sci., 88, 248-252.
27. Florence A.T. (1997): The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm. Res., 14, 259-266.
28. Chen H., Langer R. (1988): Oral particulate delivery: status and future trends. Adv. Drug Deliv. Rev., 34, 339-350.
29. LeFevre M.E., Vanderhoff J.W., Laissue J.A., Joel D.D. (1978): Accumulation of 2-micron latex particles in mouse Peyer's patches during chronic latex feeding. Experientia, 34, 120-122.
30. Lefevre M.E., Joel D.D., Schidlovski G. (1985): Retention of ingested latex particles in Peyer's patches of germfree and conventional mice. Proc. Soc. Exp. Biol. Med., 179, 522-528.
31. LeFevre M.E., Joel D.D. (1986): Distribution of label after intragastric administration of 7Be-labeled carbon to weanling and aged mice. Proc. Soc. Exp. Biol. Med., 182, 112-119.
32. Jani P., Halbert G.W., Langridge J., Florence A.T. (1989): The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol., 41, 809-812.
33. Aramaki Y., Tomizawa H., Hara T., Yachi H., Tsuchiya S. (1993): Stability of liposomes in vitro and their uptake by rat Peyer's patches following oral administration. Pharm. Res., 10, 1228-1231.
34. Senior K. (2001): Bilosomes: the answer to oral vaccine delivery? Drug Disco Today, 6, 1031-1032.
35. Pappo J. (1989): Generation and characterization of monoclonal antibodies recognizing follicle epithelial M cells in rabbit gut-associated lymphoid tissues. Cell. Immunol. 120: 31-41.
36. Maury J., Nicoletti C., Guzzo-Chambraud L., Maroux S. (1995): The filamentous brush border glycocalyx, a mucin-like marker of enterocyte hyper-polarization. Eur. J. Biochem., 228, 323-31.
37. Frey A., Giannasca K.T., Weltzin R.G., Giannasca P.J., Reggio H., Lencer W.I., Neutra M.R. (1996): Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J. Exp. Med., 184, 1045-1059.
38. Neutra M.R. (1998): Current concepts in mucosal immunity. V Role of M cells in transepithelial transport of antigens and pathogens to the mucosal immune system. Am. J. Physiol., 274,785-791.
39. Walde P., Sunamoto J., O'Connor J. (1987): The mechanism of liposomal damage by taurocholate. Biochim. Biophys. Acta, 905, 30-38.
40. O'Connor C.J., Wallace R.G., Iwamoto K., Taguchi T., Sunamoto J. (1985): Bile salt damage of egg phosphatidylcholine liposomes. Biochim. Biophys. Acta, 817, 95-102.